Four details:
1. Pacira’s bupivacaine liposome injectable suspension product is used in a variety of procedures, including orthopedic and spine surgeries.
2. The FDA approved Exparel for adults in 2011 and now will allow surgeons to use the product for pediatric patients ages 6 years and older.
3. Exparel is the first long-acting local anesthetic approved for pediatric use. The approval is based on a phase 3 study of Exparel in pediatric patients undergoing spine and cardiac procedures, which found no safety concerns.
4. More than 8 million patients have received Exparel for nonopioid pain control.
More articles on anesthetics:
How incorrectly documenting your anesthesia service can cost you your reimbursement
7 anesthesia company notes so far in 2021
Anesthesia market to hit $2.4B by 2025, market report says
